Author:
Gonelli Arianna,Radillo Oriano,Drioli Sara,Rimondi Erika,Secchiero Paola,Maria Bonora Gian
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference21 articles.
1. Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331–340
2. Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126–135
3. Secchiero P, Zauli G (2008) TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 15:42–48
4. Soria JC, Smit E, Khayat D et al (2010) Phase 1b study of Dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non–small-cell lung cancer. J Clin Oncol 28:1527–1533
5. Kelley SK, Harris LA, Xie D et al (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31–38
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献